Find stories of hope, told by the people who motivate us every day to continue changing the standard in cancer care.
Each cell therapy we develop is uniquely designed for each patient, harnessing the power of the immune system to target and attack cancer. Our CAR T-cell therapy manufacturing process includes these 5 steps:
May 21, 2026
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in OncologyApril 28, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celFebruary 23, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celFebruary 06, 2026
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma